Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) Net Income towards Common Stockholders (2016 - 2025)

Apyx Medical's Net Income towards Common Stockholders history spans 15 years, with the latest figure at -$1.3 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 71.93% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached -$11.2 million, up 52.22%, while the annual FY2025 figure was -$11.2 million, 52.22% up from the prior year.
  • Net Income towards Common Stockholders reached -$1.3 million in Q4 2025 per APYX's latest filing, up from -$2.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.0 million in Q2 2023 to a low of -$9.6 million in Q4 2023.
  • Average Net Income towards Common Stockholders over 5 years is -$4.6 million, with a median of -$4.6 million recorded in 2023.
  • Peak YoY movement for Net Income towards Common Stockholders: surged 81.3% in 2023, then tumbled 543.38% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$2.0 million in 2021, then crashed by 201.74% to -$6.1 million in 2022, then tumbled by 58.4% to -$9.6 million in 2023, then skyrocketed by 51.83% to -$4.6 million in 2024, then soared by 71.93% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Net Income towards Common Stockholders are -$1.3 million (Q4 2025), -$2.0 million (Q3 2025), and -$3.8 million (Q2 2025).